Xenon Pharmaceuticals (XENE) Accumulated Expenses (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Accumulated Expenses of $32.5 million for Q1 2026, up 544.07% year-over-year from $5.0 million in Q1 2025, and down 10.64% quarter-over-quarter from $36.4 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Accumulated Expenses (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Accumulated Expenses for 14 consecutive years, with $32.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 544.07% year-over-year to $32.5 million; the TTM figure through Mar 2026 stood at $32.5 million (up 544.07% YoY), while the FY2025 annual figure was $36.4 million, up 201.59% from the prior year.
- Accumulated Expenses slipped to $32.5 million in Q1 2026 per XENE's latest filing, from $36.4 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $36.4 million in Q4 2025 and bottomed at $2.1 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $10.3 million across 5 years, with a median of $5.9 million in 2023.
- Annual changes were most pronounced in 2022 — Accumulated Expenses fell 1.97% — and 2026, when it soared 544.07%.
- Xenon Pharmaceuticals' Accumulated Expenses stood at $5.8 million in 2022, then jumped by 51.54% to $8.8 million in 2023, then jumped by 36.68% to $12.1 million in 2024, then jumped by 201.59% to $36.4 million in 2025, then decreased by 10.64% to $32.5 million in 2026.
- Business Quant data shows XENE's Accumulated Expenses at $32.5 million in Q1 2026, $36.4 million in Q4 2025, and $17.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.19 Mn |
| Mar 31, 2026 | 32.51 Mn |
| Dec 31, 2025 | 36.38 Mn |
| Sep 30, 2025 | 17.50 Mn |
| Jun 30, 2025 | 15.25 Mn |
| Mar 31, 2025 | 5.05 Mn |
| Dec 31, 2024 | 12.06 Mn |
| Sep 30, 2024 | 8.94 Mn |
| Jun 30, 2024 | 6.20 Mn |
| Mar 31, 2024 | 3.82 Mn |
| Dec 31, 2023 | 8.82 Mn |
| Sep 30, 2023 | 5.85 Mn |
| Jun 30, 2023 | 4.93 Mn |
| Mar 31, 2023 | 2.67 Mn |
| Dec 31, 2022 | 5.82 Mn |
| Sep 30, 2022 | 4.22 Mn |
| Jun 30, 2022 | 3.32 Mn |
| Mar 31, 2022 | 2.11 Mn |
| Dec 31, 2021 | 5.94 Mn |
| Sep 30, 2021 | 3.38 Mn |